An FDA inspector arrives unannounced at a pharmaceutical manufacturing facility and requests maintenance records for every critical production asset within 15 minutes. Without a validated system of record, manufacturers risk warning letters, production delays and even production shutdowns. That high-stakes reality underscores why asset management in life sciences is fundamentally different. Instead of adapting a general-purpose asset management platform to meet regulated manufacturing requirements, Blue Mountain developed its Regulatory Asset Manager (RAM) platform exclusively for life sciences manufacturing. The purpose-built approach helps pharmaceutical, biotech, cell and gene therapy, medical device and other regulated life sciences manufacturers manage regulated assets throughout their lifecycle while improving compliance, efficiency and scalability. Compliance Without Compromise Unlike horizontal enterprise asset management platforms, Blue Mountain RAM was designed around the cGMP requirements and operating realities of life sciences manufacturers. Its domain-specific approach delivers pre-validated workflows based on industry best practices, reducing customization, simplifying compliance, accelerating implementation and lowering long-term maintenance and ownership costs. “Life sciences manufacturers shouldn’t have to adapt a general-purpose EAM to meet cGMP requirements,” says David Hall Rode, CEO of Blue Mountain. “We built RAM around the way regulated manufacturers actually operate.”.

AI can write a 10-page clinical narrative in a fraction of the time it takes a medical writer. In life sciences, that is where the harder question begins: Can every sentence be trusted? A large clinical trial may require thousands of patient narratives; each built from dense clinical data and ultimately subject to regulatory review. Speed helps, but not if it comes at the expense of accuracy or traceability. Narrativa has been building around that tension since 2015. As its technology evolved from natural language processing and machine learning to large language models and AI agents, its principle stayed fixed: AI-generated documentation should never become a black box..

PDA Laboratories continues to strengthen its position as a trusted third-party testing partner for manufacturers across the cosmetics, nutraceutical, and pharmaceutical sectors. Operating from its Riverdale, New Jersey facility, the company has expanded testing capabilities making capital investments into testing equipment, strengthening expertise, and enhancing services that help clients navigate increasingly complex regulatory expectations. Since its establishment, PDA Laboratories has focused on combining scientific accuracy with responsive support. The company’s approach centers on delivering dependable microbiology and analytical testing while helping manufacturers and packaging companies protect product quality, consumer safety, and brand reputation. Its continued growth reflects a commitment to practical solutions that address real production challenges..

No matter the age, some women exude a certain glow—a confidence and radiance that feels almost magnetic. While we might attribute it to expensive skincare or sheer luck, the truth lies not only in external care but also in internal balance. Honoring the body’s true needs, particularly in hormonal balance and cellular vitality, can empower anyone to embrace a vibrant, radiant life that feels as good as it looks. Glow Natural Wellness champions this approach, offering solutions designed to honor the body’s natural wisdom and strength—not quick fixes. Led by naturopathic physician Dr. Michelle Sands, the company combines science and nature to deliver cruelty-free products free of toxins, fillers, and synthetic ingredients, specifically for women over 40. These affordable, accessible, and uncompromising products are designed to help women balance their hormones and thrive at any age. Each supplement, holistic hormone balancing solutions, and cosmetic item is free of fillers, sugars, gluten, parabens, plastics, or petrochemicals, delivering only what a woman’s body truly needs. “Specializing in perimenopause and menopause, I bring a potent mix of endocrinology, genetics, functional nutrition, and anti-aging expertise to the table. Every formula is crafted with care, attention, and a deep understanding of women’s health,” says Dr. Michelle Sands, founder and CEO of Glow Natural Wellness. Supplements That Support Women’s Wellness from Within Glow Natural Wellness journey began when Dr. Sands faced sudden ovarian failure and menopause symptoms before she was even old enough to buy a drink. The solutions she was offered failed to address the root cause of her health issues. Through her personal trial-and-error journey, she realized that many women feel overwhelmed by conflicting advice about their health at different life stages. According to Dr. Sands, no woman should have to choose between her health and her values..

When regulatory strategy is embedded into clinical trial design, the difference is tangible—faster timelines and an easier path to market. CCS Associates (CCSA) has designed some of modern medicine's most complex and impactful clinical programs for more than four decades, fueling the development of life-altering diagnostic, preventive and therapeutic medical products. A woman-owned small business, CCSA provides leading-edge advisory and regulatory services in product discovery and development. Over the years, the company has played a key role in designing industry-grade master protocols and investigational new drug applications (INDs) like those for Lung-MAP and I-SPY 2, which have been in use for over a decade. Backed by in-depth expertise, it empowers nimble biotech startups and major government institutions to lead every stage of clinical development with clarity and confidence. “Our vast experience in handling regulatory affairs for several ground-breaking master protocols and INDs gives us a competitive edge,” says Linda A. Doody, Executive Director. A highly skilled leadership team with deep scientific knowledge is at the heart of the company’s operations. Dr. Doody has been with CCSA for over 35 years and has built the regulatory and safety departments from the ground up. Its unparalleled scientific acumen is the result of government partnerships, including programs with the National Heart, Lung and Blood Institute (NHLBI) and NIH’s Blueprint Neurotherapeutics Network (BPN). Many of CCSA’s commercial clients are referrals from previous government-sponsored collaborations. They rely on its hands-on approach and scientific depth to improve the odds of clinical trial success. In one instance, a company operating with a skeleton crew partnered with CCSA through the BPN program. Today, the organization runs phase 3 trials in multiple countries, with CCSA supporting its U.S. regulatory strategy. Long-term commitment is a core principle at CCSA. It guides early-stage innovators through complex clinical trials by staying on board beyond IND submission. Whether it’s ophthalmologic treatments, neurodegenerative disease therapeutics, cancer prevention or age-related drug development, the company delivers unparalleled scientific and strategic support throughout the entire R&D process. “We very often function as members of our clients’ teams, integrating ourselves into projects and working very closely with clients’ staff,” says Dr. Caroline C. Sigman, President and CEO. CCSA’s proficiency in managing INDs has been instrumental in conceptualizing and executing numerous master protocols. The I-SPY 2 platform’s transformational impact on breast cancer research is a perfect example. Designed to simultaneously evaluate multiple treatments using a shared control arm and adaptive design, I-SPY 2 delivers real-time insights and accelerates drug development..